Supplementary Tables 1-8 from Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions

Authors:

Open Access

31 March 2023

other
Published by American Association for Cancer Research (AACR)

DOI:10.1158/1078-0432.22462265

Abstract

Supplementary Tables 1-8 and Supplementary Figures 1-3 legends Supplementary Table 1: List of Investigators for the HEAT Study Supplementary Table 2: Summary of RFA Treatment Supplementary Table 3: Stepwise Multivariate Cox Modelling Results Supplementary Table 4: Overall Survival According to Stage Supplementary Table 5: Evaluation of Treatment Failure Supplementary Table 6: Overview of Treatment-Emergent Adverse Events Supplementary Table 7: Treatment-Emergent Adverse Events by Preferred Term Supplementary Table 8: Key Treatment-Emergent Adverse Events Among Subjects With a Solitary Tumor by 45-Minute RFA Cutpoint

Keywords

TABLE (DATABASE)